UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Molecular Mechanisms of the Cardiotoxicity of the Proteasomal-Targeted Drugs Bortezomib and Carfilzomib

Cardiovascular toxicology, 2017-07, Vol.17 (3), p.237-250

2017

Volltextzugriff (PDF)

Mechanisms of the Cardiac Myocyte-Damaging Effects of Dasatinib

Cardiovascular toxicology, 2020-08, Vol.20 (4), p.380-389

2020

Volltextzugriff (PDF)

The Role of Topoisomerase IIβ in the Mechanisms of Action of the Doxorubicin Cardioprotective Agent Dexrazoxane

Cardiovascular toxicology, 2020-06, Vol.20 (3), p.312-320

2020

Volltextzugriff (PDF)

Dexrazoxane use in the prevention of anthracycline extravasation injury

Future oncology (London, England), 2006-02, Vol.2 (1), p.15-20

Hasinoff, Brian B

2006

Volltextzugriff (PDF)

Dexrazoxane: how it works in cardiac and tumor cells. Is it a prodrug or is it a drug?

Cardiovascular toxicology, 2007-06, Vol.7 (2), p.140-144

2007

Volltextzugriff (PDF)

Dexrazoxane (ICRF-187) protects cardiac myocytes against doxorubicin by preventing damage to mitochondria

Cardiovascular toxicology, 2003, Vol.3 (2), p.89-100

2003

Volltextzugriff (PDF)

A review of the preclinical development of dexrazoxane

Progress in pediatric cardiology, 2014-09, Vol.36 (1), p.33-38

2014

Volltextzugriff (PDF)

The antitumor anthracyclines doxorubicin and daunorubicin do not inhibit cell growth through the formation of iron-mediated reactive oxygen species

Anti-cancer drugs, 2005-01, Vol.16 (1), p.93-99

2005

Volltextzugriff (PDF)

Dexrazoxane (ICRF-187) protects cardiac myocytes against hypoxia-reoxygenation damage

Cardiovascular toxicology, 2002, Vol.2 (2), p.111-118

Hasinoff, Brian B

2002

Volltextzugriff (PDF)

The iron chelating cardioprotective prodrug dexrazoxane does not affect the cell growth inhibitory effects of bleomycin

Journal of inorganic biochemistry, 2004-11, Vol.98 (11), p.1818-1823

2004

Volltextzugriff (PDF)

The displacement of iron(III) from its complexes with the anticancer drugs piroxantrone and losoxantrone by the hydrolyzed form of the cardioprotective agent dexrazoxane

Journal of inorganic biochemistry, 1999-11, Vol.77 (3), p.257-259

1999

Volltextzugriff (PDF)

The effect of the catalytic topoisomerase II inhibitor dexrazoxane (ICRF-187) on CC9C10 hybridoma viability and productivity

Cytotechnology (Dordrecht), 2001-10, Vol.37 (2), p.107-117

2001

Volltextzugriff (PDF)

Synthesis and characterization of the biological activity of the cisplatin analogs, cis-PtCl2(dexrazoxane) and cis-PtCl2(levrazoxane), of the topoisomerase II inhibitors dexrazoxane (ICRF-187) and levrazoxane (ICRF-186)

Journal of inorganic biochemistry, 2004-04, Vol.98 (4), p.616-624

2004

Volltextzugriff (PDF)

Synthesis and characterization of the biological activity of the cisplatin analogs, cis-PtCl 2(dexrazoxane) and cis-PtCl 2(levrazoxane), of the topoisomerase II inhibitors dexrazoxane (ICRF-187) and levrazoxane (ICRF-186)

Journal of inorganic biochemistry, 2004, Vol.98 (4), p.616-624

2004

Volltextzugriff (PDF)

Inhibition of anthracycline semiquinone formation by ICRF-187 (Dexrazoxane) in cells

Free radical biology & medicine, 1996, Vol.20 (7), p.905-914

1996

Volltextzugriff (PDF)

Doxorubicin Reduces the Iron(III) Complexes of the Hydrolysis Products of the Antioxidant Cardioprotective Agent Dexrazoxane (ICRF-187) and Produces Hydroxyl Radicals

Archives of biochemistry and biophysics, 1995-02, Vol.316 (2), p.680-688

1995

Volltextzugriff (PDF)

Ferrous Ion Strongly Promotes the Ring Opening of the Hydrolysis Intermediates of the Antioxidant Cardioprotective Agent Dexrazoxane (ICRF-187)

Archives of biochemistry and biophysics, 1995-02, Vol.317 (1), p.121-127

1995

Volltextzugriff (PDF)

A quantitative structure?activity relationship study of the rate of imide hydrolysis as a predictive model for the hydrolysis-activation of analogs of the cardioprotective agent dexrazoxane

Journal of molecular modeling, 2001-01, Vol.7 (12), p.438-444

2001

Volltextzugriff (PDF)

1 – 18 von 18

Suche als RSS-Feed

Aktive Filter

ThemaPharmacology & Pharmacy

ThemaDexrazoxane

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(18)
Mit Volltextzugriff
(17)

Publikationsform

Artikel
(18)

Sprache

Englisch
(18)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(13)
Science & Technology
(13)
Doxorubicin
(11)
Animals
(8)
Iron
(8)
Biochemistry & Molecular Biology
(7)
Razoxane - Pharmacology
(7)
Cardiotoxicity
(6)
Anthracycline
(5)
Cardiac & Cardiovascular Systems
(5)
Cardiovascular Agents - Pharmacology
(5)
Cardiovascular System & Cardiology
(5)
Hydrolysis
(5)
Myocytes, Cardiac - Drug Effects
(5)
Rats, Sprague-Dawley
(5)
Razoxane
(5)
Apoptosis
(4)
Chemistry
(4)
Dna Topoisomerase
(4)

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Molecular Mechanisms of the Cardiotoxicity of the Proteasomal-Targeted Drugs Bortezomib and Carfilzomib

Mechanisms of the Cardiac Myocyte-Damaging Effects of Dasatinib

The Role of Topoisomerase IIβ in the Mechanisms of Action of the Doxorubicin Cardioprotective Agent Dexrazoxane

Dexrazoxane use in the prevention of anthracycline extravasation injury

Dexrazoxane: how it works in cardiac and tumor cells. Is it a prodrug or is it a drug?

Dexrazoxane (ICRF-187) protects cardiac myocytes against doxorubicin by preventing damage to mitochondria

A review of the preclinical development of dexrazoxane

The antitumor anthracyclines doxorubicin and daunorubicin do not inhibit cell growth through the formation of iron-mediated reactive oxygen species

Dexrazoxane (ICRF-187) protects cardiac myocytes against hypoxia-reoxygenation damage

The iron chelating cardioprotective prodrug dexrazoxane does not affect the cell growth inhibitory effects of bleomycin

The displacement of iron(III) from its complexes with the anticancer drugs piroxantrone and losoxantrone by the hydrolyzed form of the cardioprotective agent dexrazoxane

The effect of the catalytic topoisomerase II inhibitor dexrazoxane (ICRF-187) on CC9C10 hybridoma viability and productivity

Synthesis and characterization of the biological activity of the cisplatin analogs, cis-PtCl2(dexrazoxane) and cis-PtCl2(levrazoxane), of the topoisomerase II inhibitors dexrazoxane (ICRF-187) and levrazoxane (ICRF-186)

Synthesis and characterization of the biological activity of the cisplatin analogs, cis-PtCl 2(dexrazoxane) and cis-PtCl 2(levrazoxane), of the topoisomerase II inhibitors dexrazoxane (ICRF-187) and levrazoxane (ICRF-186)

Inhibition of anthracycline semiquinone formation by ICRF-187 (Dexrazoxane) in cells

Doxorubicin Reduces the Iron(III) Complexes of the Hydrolysis Products of the Antioxidant Cardioprotective Agent Dexrazoxane (ICRF-187) and Produces Hydroxyl Radicals

Ferrous Ion Strongly Promotes the Ring Opening of the Hydrolysis Intermediates of the Antioxidant Cardioprotective Agent Dexrazoxane (ICRF-187)

A quantitative structure?activity relationship study of the rate of imide hydrolysis as a predictive model for the hydrolysis-activation of analogs of the cardioprotective agent dexrazoxane

Aktive Filter

Suchergebnisse filtern